应用国产人基因重组红细胞生成素治疗肾性贫血

TREATMENT OF RENAL ANEMIA WITH RECOMBINANT HUMAN ERYTHROPOIETIN MADE IN CHINA

目的：证实国产人基因重组红细胞生成素（ｒＨｕＥＰＯ）纠正终末期肾病（ＥＳＲＤ）患者肾性贫血的疗效。方法：５５例ＥＳＲＤ合并肾性贫血患者应用国产ｒＨｕＥＰＯ治疗１２周～２４周，给药方式随机分为皮下或静脉注射。结果：５４例中，４例中途退出。５１例用药前后自身对比显示：血红蛋白、红细胞压积、网织红细胞从给药第２周起显著升高（Ｐ＜００１）；白细胞、血小板、肝功能、肾功能、血清离子无明显改变（Ｐ＞００５）。应用药物剂量１２８２±２６１Ｕ／（ｋｇ·周）的疗效判定：显效率５２９％，有效率３３３％，无效率１３７％。副作用有头痛、低热、高血压等，发生率１２７％（７／５５）。结论：国产ｒＨｕＥＰＯ能安全有效纠正肾性贫血，副作用轻微。

Objective:To prove the effect of recombinant human erythropoietin(rHuEPO)made in China to treat renal anemia of end stage renal disease(ESRD).Methods:55 ESRD patients with anemia received treatment of the rHuEPO for 12 24 weeks.The rHuEPO was administered subcutaneously or intravenously.4 patients had withdrawn from the treatment.Results:After application of rHuEPO,self comparison was monitored with initial treatment phase in 51 patients.Hb,HCT,reticulocyte counts increased significantly after 2 weeks( P <0 01).There was no significant change in WBC or platelet counts,and liver and renal function( P >0 05).Significant effective rate was 52 9%,effective rate was 33 3%,ineffective rate was 13 7% in average dose of 128 2±26 1 U/(kg·w).Side effects(headache,slight fever,hypertension)was low(7/55,12 7%).Conclusion:The rHuEPO made in China was effective and safe,and there were small side effects in treating ESRD patients with renal anemia.